(HALO) Halozyme Therapeutics - Performance 55.9% in 12m
Compare HALO with Indices, Sectors and Commodities and Bonds. Who performs better in which timeframe?
Performance Rating
65.98%
#9 in Group
Rel. Strength
91.54%
#647 in Universe
Total Return 12m
55.87%
#22 in Group
Total Return 5y
265.12%
#13 in Group
P/E 18.6
57th Percentile in Group
P/E Forward 13.9
48th Percentile in Group
PEG -2.50
9th Percentile in Group
FCF Yield 5.32%
98th Percentile in Group
12m Total Return: HALO (55.9%) vs XBI (-11%)

5y Drawdown (Underwater) Chart

Top Performers in Biotechnology
Overall best picks of Peer Group Selected by proven GARP Predictive Metrics, sorted by Growth Rating
Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability |
EPS CAGR |
---|---|---|---|---|---|---|---|---|
ABBV NYSE AbbVie |
-2.97% | 17.7% | 234% | 84.1 | 16.4 | 0.42 | -49.6% | -19% |
UTHR NASDAQ United Therapeutics |
0.72% | 36.6% | 226% | 13 | 11.3 | 1.43 | 83.8% | 78.5% |
HLN NYSE Haleon |
-3.97% | 23.4% | 39.7% | 25.6 | 20.9 | 1.85 | -38.6% | -24.4% |
AMGN NASDAQ Amgen |
-1.63% | 14.1% | 68.5% | 40.5 | 14.8 | 1.04 | -18.8% | -20% |
LONN SW Lonza |
-7.89% | 0.58% | 37% | 60.5 | 31.8 | 1.16 | 12.6% | -10.3% |
NBIX NASDAQ Neurocrine Biosciences |
-5.39% | -21.4% | 18.7% | 33.6 | 22.8 | 0.27 | 61.5% | 31.6% |
BIM PA Biomerieux |
1.3% | 15.8% | 12.1% | 31.4 | 25.8 | 1.47 | -47.6% | -26.9% |
KMDA NASDAQ Kamada |
1.65% | 24.1% | 14.1% | 27 | 25 | 1 | 58.7% | 15% |
Performance Comparison: HALO vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for HALO
Total Return (including Dividends) | HALO | XBI | S&P 500 |
---|---|---|---|
1 Month | 8.73% | -5.85% | -3.01% |
3 Months | 31.26% | -11.95% | -3.15% |
12 Months | 55.87% | -11.00% | 10.19% |
5 Years | 265.12% | 0.65% | 129.24% |
Trend Score (consistency of price movement) | HALO | XBI | S&P 500 |
1 Month | 69.5% | -59.8% | -5.5% |
3 Months | 97.2% | -70.5% | -58.4% |
12 Months | 57.5% | -6.9% | 84.1% |
5 Years | 51.4% | -50% | 84.4% |
Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
1 Month | #32 | 15.5% | 12.1% |
3 Month | #11 | 49.1% | 35.5% |
12 Month | #22 | 75.1% | 41.5% |
5 Years | #12 | 263% | 59.3% |
FAQs
Does HALO Halozyme Therapeutics outperforms the market?
Yes,
over the last 12 months HALO made 55.87%, while its related Sector, the SPDR S&P Biotech (XBI) made -11.00%.
Over the last 3 months HALO made 31.26%, while XBI made -11.95%.
Over the last 3 months HALO made 31.26%, while XBI made -11.95%.
Performance Comparison HALO vs Indeces and Sectors
HALO vs. Indices HALO is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
US S&P 500 | SPY | -0.53% | 11.7% | 8.49% | 45.7% |
US NASDAQ 100 | QQQ | 0.45% | 12.8% | 9.26% | 47.3% |
US Dow Jones Industrial 30 | DIA | -0.73% | 10.9% | 7.57% | 46.4% |
German DAX 40 | DAX | 0.77% | 12.1% | -8.30% | 34.2% |
Shanghai Shenzhen CSI 300 | CSI 300 | -0.24% | 8.50% | 23.7% | 46.8% |
Hongkong Hang Seng | HSI | -2.50% | 5.96% | 17.7% | 38.5% |
India NIFTY 50 | INDA | -1.56% | 0.86% | 18.8% | 55.2% |
Brasil Bovespa | EWZ | -0.64% | 0.44% | 16.5% | 67.6% |
HALO vs. Sectors HALO is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
Communication Services | XLC | 1.01% | 12.5% | 0.38% | 36.7% |
Consumer Discretionary | XLY | -1.29% | 12.6% | 5.13% | 41.8% |
Consumer Staples | XLP | -3.32% | 10.6% | 7.65% | 44.8% |
Energy | XLE | -1.62% | 0.71% | 2.91% | 55.1% |
Financial | XLF | -1.01% | 11.4% | -3.67% | 33.6% |
Health Care | XLV | -0.95% | 11.9% | 13.2% | 54.2% |
Industrial | XLI | -0.84% | 9.42% | 9.20% | 47.3% |
Materials | XLB | -1.63% | 8.22% | 16.6% | 59.8% |
Real Estate | XLRE | -2.57% | 11.4% | 11.6% | 42.5% |
Technology | XLK | 0.60% | 12.7% | 13.6% | 53.9% |
Utilities | XLU | -3.82% | 7.91% | 9.37% | 30.6% |
Aerospace & Defense | XAR | 0.07% | 7.45% | 4.57% | 34.9% |
Biotech | XBI | 4.03% | 14.6% | 26.2% | 66.9% |
Homebuilder | XHB | -1.03% | 8.58% | 27.9% | 63.6% |
Retail | XRT | -2.83% | 9.23% | 12.6% | 60.7% |